Salt Lake City-based Huntsman Cancer Institute at the University of Utah will be the first U.S. academic medical center to manufacture a novel prostate cancer imaging drug, flotufolastat F 18.
The drug was developed by Blue Earth Diagnostics and will be manufactured through Huntsman Cancer Institute’s Center for Quantitative Cancer Imaging and Theranostics, according to a Feb. 10 news release from the institute.
Flotufolastat F 18, also known as Posluma, enables more accurate detection and staging of prostate cancer tumors by binding to cells that express a prostate-specific membrane antigen.
Posluma will be the third prostate-specific membrane antigen drug manufactured at Huntsman Cancer Institute, the release said.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
